How different are the costs and consequences of delayed versus immediate HIV treatment?
dc.contributor.author | Welte A. | |
dc.contributor.author | Hargrove J. | |
dc.contributor.author | Delva W. | |
dc.contributor.author | Williams B. | |
dc.contributor.author | Stander T. | |
dc.date.accessioned | 2011-10-13T16:58:51Z | |
dc.date.available | 2011-10-13T16:58:51Z | |
dc.date.issued | 2011 | |
dc.description.abstract | [No abstract available] | |
dc.description.version | Article | |
dc.identifier.citation | South African Medical Journal | |
dc.identifier.citation | 101 | |
dc.identifier.citation | 6 | |
dc.identifier.citation | http://www.scopus.com/inward/record.url?eid=2-s2.0-79958056702&partnerID=40&md5=2b2c153df2f5399c89b6bf31e6650399 | |
dc.identifier.issn | 2569574 | |
dc.identifier.uri | http://hdl.handle.net/10019.1/16883 | |
dc.subject | antiretrovirus agent | |
dc.subject | article | |
dc.subject | cost benefit analysis | |
dc.subject | early intervention | |
dc.subject | endemic disease | |
dc.subject | health care | |
dc.subject | health care cost | |
dc.subject | health care delivery | |
dc.subject | health care policy | |
dc.subject | highly active antiretroviral therapy | |
dc.subject | human | |
dc.subject | Human immunodeficiency virus infection | |
dc.subject | incidence | |
dc.subject | life expectancy | |
dc.subject | South Africa | |
dc.subject | therapy delay | |
dc.title | How different are the costs and consequences of delayed versus immediate HIV treatment? | |
dc.type | Article |